Objective: To examine whether middle (two months) and long-term (six months) isradipine sustained-release treatment improves endothelium-dependent vasodilation in never treated hypertensive patients. Methods: The responses of the forearm vasculature to acetylcholine (7.5, 15 and 30 mg / min) and sodium nitroprusside (0.8, 1.6, 3.2 mg / min) were evaluated in 12 normotensive controls (seven men and five women, aged 25 to 49 years), and in 12 hypertensives (eight men and four women, aged 20 to 47 years) at baseline and after two and six months of isradipine sustained-release treatment. Drugs were infused into the brachial artery, and forearm blood flow was measured by strain-gauge plethysmography. Results: At baseline, the response to acetylcholine was significantly lower in hypertensives vs controls: at the highest dose (30 mg / min), forearm blood flow was 28.662.4 ml / 100 ml of tissue per min in the controls vs 8.961.0 ml / 100 ml of tissue per min in hypertensives ( p,0.0001). Similarly, vascular resistance was significantly ( p,0.0001) higher in hypertensives: 4.860.5 units (controls) vs 15.161.7 units (hypertensives). After isradipine treatment, the forearm blood flow in hypertensive patients changed from 8.961.0 ml / 100 ml of tissue per min to 16.061.2 ml / 100 ml of tissue per min (two months; p,0.0001) and 15.261.4 ml / 100 ml of tissue per min (six months; p,0.0001). Isradipine treatment did not modify the vasodilating effect of sodium nitroprusside. Conclusions: Our data demonstrate for the first time that the calcium antagonist isradipine improves acetylcholine-induced vasodilation in hypertensives.
Introduction
inorganic source of NO [8] . The role of NO in human essential hypertension was investigated by comparing the The normal endothelium plays a key role in the local vasodilator response to ACh and to SNP in the brachial or regulation of the vascular tone by producing and releasing coronary arteries [9] [10] [11] . contracting and relaxing factors [1] . One of these factors is Endothelium-dependent vasodilation has been show to the endothelium-derived relaxing-factor (EDRF), identified occur in most mammalian species [2] , and in humans by in as nitric oxide (NO) [2] [3] [4] [5] [6] . NO is released after stimulavitro studies using arterial preparations [12, 13] . Subtion of endothelial cells by some physical stimuli, such as sequent, human studies have confirmed these experimental shear stress and blood flow [7] , as well as some agonists findings, and have demonstrated that this regulatory action such as acetylcholine (ACh), bradykinin, substance P, and of the endothelium is exerted on resistance vessels also serotonin [6] . On the contrary, sodium nitroprusside (SNP) [14] . Moreover, this endothelial function is impaired in the is an endothelium-independent vasodilator compound that presence of different risk factors [9, 10, [15] [16] [17] [18] [19] [20] [21] ; in parproduces a vasodilation by direct activation of guanylate ticular, in hypertensive patients these studies, with the cyclase in vascular smooth-muscle cells by providing an exception of Cockcroft and co-workers [22] , have reported a reduced endothelium-dependent vasodilation to ACh when compared to normotensive control subjects.
Experimental evidences suggest that neither calciumsubjects and hypertensive patients with a dose-response to channel blocker (CCB) nifedipine [23] nor ACE-inhibitors intra-arterial ACh and SNP infusions, respectively. [24, 25] , with the exception of Hirooka [26] may improve Successively, after the first evaluation in hypertensive endothelium-dependent vascular relaxation in hypertensive patients we administered isradipine sustained-release (5  patients. mg / day) for six months. Clinical evaluations were Isradipine is a potent CCB of the dihydropyridine class scheduled every four weeks to evaluate BP values and / or and has been shown to be an effective first-line monopossible adverse effects. therapeutic antihypertensive drug [27] [28] [29] . Moreover, it Finally, in hypertensive patients the vascular function was reported that isradipine treatment partly prevented has been re-evaluated after two (middle term) and six endothelial dysfunction induced by hypercholesterolemia, months (long-term) of isradipine once-a-day administraand reduced structural and biological changes of atherotion. To assess the reproducibility of endothelium-depensclerosis [30] . dent and endothelium-independent vasodilation, the vascuThe aim of this study was to evaluate whether middle lar function in the normotensive group was reevaluated (two months) and long-term (six months) treatment with after two months again. CCB isradipine improves endothelium-dependent vasodilation in the forearm resistance vessel of patients with 2.3. Blood pressure measurements essential hypertension.
Clinical BP measurements were obtained in the morning between 8:00 a.m. and noon. BP was measured three times with a mercury sphygmomanometer. The mean of the last 2. Methods two measurements was used. Hypertension was defined as a systolic BP.160 mmHg, a diastolic BP.95 mmHg, or 2.1. Study population both. A physician made measurements with the subject seated for at least 5 min.
Hypertensive patients
Ambulatory BP monitoring (ABPM) was recorded using Twelve never treated outpatients, eight men and four an A&T TM 2420 recorder, model 7 (Takeda, Tokyo, women, aged 20 to 47 years (mean6SEM537.161.8 Japan), validated in accordance with the protocol of the years), with well documented history of primary hypertenBritish Society of Hypertension [31] . The portable BP sion were recruited for the study. All patients underwent recorder employs a dual microphone system in a physical examination and review of their medical histories sphygmomanometer cuff to record the Korotkoff sounds. before entering the trial. Causes of secondary hypertension Recordings were taken every 10 min during the day (from were excluded in all patients. None of the patients had a 07.00 a.m. to 11.00 p.m.) and every 20 min during the history of diabetes, hyperlipidemia, peripheral vascular night (from 11.00 p.m. to 7.00 a.m.). The patients were disease, coagulopathy, or any disease predisposing them to invited to observe these periods of rest and activity closely. vasculitis or Raynaud's phenomenon. Diagnosis of essenWhen the device was operating, patients were asked to tial hypertension was obtained in all patients for the first remain motionless and keep their arm still. time when they were recruited for the study. None of the Mean values of heart rate (HR), systolic, diastolic and participants were taking antihypertensive therapy. mean BP were calculated in each patient hour by hour, and averaged throughout the 24-h, and the day-and night-time 2.1.2. Normotensive subjects periods. Twelve normal volunteers, seven men and five women, aged 25 to 49 years (mean6SEM537.761.7 years), were 2.4. Measurements of forearm blood flow selected as a control group. Each patient underwent clinical history, physical examination, standard electrocardiogram, All studies were performed at 9:00 a.m. after overnight routine chemical analyses, and chest X-rays. None had fasting, with the subjects lying supine in a quiet airevidence of present or past hypertension, cardiovascular conditioned room (228 to 248C). The subjects were indisease, hyperlipidemia, or any other systemic condition, structed to continue their regular diet; caffeine and alcohol and none were taking drugs at the time of the study.
were all prohibited 24 h before the study. Forearm volume The local ethical committee approved the study, and all was evaluated according to the water-displacement methparticipants gave written informed consent for all prood. Under local anesthesia and sterile conditions, a 20-cedures.
gauge polyethylene catheter (Vasculon 2) was inserted into the brachial artery of the nondominant arm (left, in most 2.2. Study protocol cases) of each subject for evaluation of BP (Baxter Healthcare) and for drug's infusion. This arm was slightly At first, both endothelium-dependent and endotheliumelevated above the level of the right atrium, and a mercuryindependent vasodilation was evaluated in normotensive filled silastic strain-gauge was placed on the widest part of the forearm [32] . The strain-gauge was connected to a immediately before infusion. SNP (Malesci, Florence, plethysmograph (model EC-4, D.E. Hokanson, Issaquah, Italy) was diluted in 5% glucose solution immediately WA) [33] calibrated to measure the percent change in before each infusion and protected from light with volume; this was connected to a chart recorder to obtain aluminum foil. Isradipine capsules were provided from the forearm blood flow (FBF) measurements. A cuff Sandoz (Milan, Italy). placed on the upper arm was inflated to 40 mmHg with a rapid cuff inflator (model E-10 Hokanson, Issaquah, WA) 2.7. Statistical analysis to exclude venous outflow from the extremity. A wrist cuff was inflated to BP values 1 min before each measurement Differences between means were compared by paired to exclude the hand blood flow. The FBF of the opposite and unpaired Student's t-test, as appropriate. The rearm was also evaluated during the study.
sponses to SNP and ACh were compared by ANOVA for The FBF was measured as the slope of the change in the repeated measurements and when analysis was significant, forearm volume. The mean of at least three measurements the Tukey's test was applied. All calculated p values are was obtained at each time point. Forearm vascular resisttwo tailed. Significant differences were assumed to be ance, as expressed in units (U), was calculated by dividing present at p,0.05. All group data are reported as mean BP by FBF. BP was recorded directly from the mean6SEM. intra-arterial catheter immediately before each measurement.
Results

Vascular function
All participants completed the protocol study. Baseline All hypertensive patients and normotensive subjects demographic, hemodynamic, and humoral characteristics underwent measurement of FBF and BP during intraare summarized in Table 1 . There were no significant arterial infusion of saline, and increasing doses of ACh and differences in plasma cholesterol, glycemia, body mass SNP. All participants rested at least 30 min after artery index and FBF between control subjects and hypertensive cannulation to obtain a stable baseline before data collecpatients. Vascular resistance in normal subjects and in tion; FBF and vascular resistance were repeated every five hypertensive group was significantly different ( p,0.05): minutes until stable.
28.161.6 U and 33.361.4 U, respectively. According to Endothelium-dependent vasodilation was evaluated by inclusion criteria, systolic and diastolic BP values were dose response curve to intra-arterial ACh infusions (7.5, 15 significantly ( p,0.0001) lower in control subjects in and 30 mg / min, each for 5 min). Endothelium-independent comparison with hypertensive patients (130 / 8063 / 1 vasodilation was assessed by the dose-response curve to mmHg vs 169 / 9965 / 2 mmHg). intra-arterial SNP infusions (0.8, 1.6, 3.2 mg / min, each for All participants were never smokers. 5 min). The sequence of administration of ACh and SNP was randomized to avoid any bias related to the order of drug infusion. The drug infusion rate was adjusted for the 3.1. Reproducibility of endothelium-dependent forearm volume of each subject. The infusion rate for each vasodilation drug was 1 ml / min.
The FBF and vascular resistance, re-evaluated in normal 2.6. Drugs subjects two months later, were not significantly different to baseline values as reported in Table 2 . Similarly, the BP ACh (Sigma, Milan, Italy) was diluted with saline and HR did not change. 
U). nificantly increased in normotensive subjects (increments
The isradipine treatment significantly increased the from basal: 2.4 ml / 100 ml of tissue per min, 8.9 ml / 100 vasodilator response to incremental doses of ACh (Fig. 1) . ml of tissue per min, 24.6 ml / 100 ml of tissue per min) compared with hypertensive patients (increments from basal: 1.0 ml / 100 ml of tissue per min, 1.9 ml / 100 ml of tissue per min, 5.3 ml / 100 ml of tissue per min). At the highest dose (30 mg / min), FBF was 28.663.4 ml / 100 ml of tissue per min in the control subjects, and 8.961.0 ml / 100 ml of tissue per min in hypertensive patients ( p,0.001) (Fig. 1) . Forearm vascular resistance during ACh infusions significantly decreased in both normotensive (decrements from basal: 29.3 U, 216.5 U, 223.3 U) and hypertensive subjects (decrements from basal: 28.1 U, 211.8 U, 218.2 U). At the highest dose, vascular resistance was 4.860.5 U in control subjects and 15.161.7 U ( p,0.0001) in hypertensive patients (Fig. 2) . Incremental ACh infusions did not change baseline BP or HR values in either group.
Significant increases in FBF (Fig. 1 ) as well as decreases in forearm vascular resistance (Fig. 2) were observed in both normotensive and hypertensive subjects during SNP infusion, although no significant differences were found between groups. At the highest dose (3.2 mg / min), FBF increased to 11.860.7 ml / 100 ml of tissue per min in the control group, and to 11.060.8 ml / 100 ml of tissue per min in hypertensive patients, respectively.
Controlateral FBF did not significantly change during the intra-arterial drug infusions. creases of vascular resistance (Fig. 2) were observed in hypertensive patients after isradipine treatment during SNP infusions. However, no significant differences with the pretreatment group were found at the different time points.
Pre-treatment versus post-treatment patients (two
Long-term (six months) versus middle-term (two months) treatment
After six months of isradipine administration, systolic and diastolic BP remained lowered from baseline values. No significant differences were observed in mean 24-h BP values after two and six months of antihypertensive therapy (Table 3) .
Similarly, after six months of isradipine treatment, the improvement of FBF (Fig. 1) and decrease of vascular resistance (Fig. 2) during incremental doses of ACh and SPN infusions were not significantly different from the values obtained after two months of antihypertensive therapy.
Side effects
No side effects were observed during the study. No patient had to discontinue treatment because of adverse reactions. Our data confirm previous studies [9, 10] showing that and SNP in hypertensives (j) are graphically reported. Data are expressed as mean6SEM. patients with essential hypertension have an impaired response to ACh infusions compared with normotensive Particularly, at the highest dose (30 mg / min), FBF was control subjects. Similarly, the observation that there were significantly enhanced from 8.961.0 ml / 100 ml of tissue no differences in the vasodilator effect of SNP between per min to 16.061.2 ml / 100 ml of tissue per min ( p, hypertensive patients and normotensive subjects excludes a 0.0001). Similarly, forearm vascular resistance was signonselective defect in responsiveness of vascular smooth nificantly reduced from 15.161.7 U to 7.561.0 U ( p, muscle cells to vasodilators in essential hypertension. 0.0001) (Fig. 2) . However, it is necessary to remark that
Discussion
The new and very interesting findings of our study are even if isradipine treatment markedly improved the FBF the demonstration that middle-term (two months) and longresponse to ACh, it still remained depressed in hypertenterm (six months) antihypertensive therapy with the CCB sives when compared with the response of normotensive isradipine improves endothelium-dependent vasodilation in subjects.
hypertensive humans. This beneficial effect of isradipine Finally, incremental ACh infusions after isradipine on endothelial function is probably specific and unrelated treatment did not change HR or systemic BP.
to BP decrease. The demonstration that hypertension-assoSignificant increases of FBF (Fig. 1 ) as well as deciated endothelial dysfunction may be reversed by a The results of our study do not provide direct insight macological treatment of essential hypertension.
into the mechanism by which CCB isradipine restores endothelial function. However it is probably not related to an interaction with surface endothelial receptors. In fact, 4.1. Endothelium-dependent vasodilation in hypertension previous reports have demonstrated that in hypertensive humans, endothelial dysfunction is not induced by an Hypertension is an important cardiovascular risk factor alteration in receptor or signal transduction pathways associated with myocardial infarction, heart failure and [42, 43] , but it is probably related to a primary or induced stroke [34] [35] [36] . Normal endothelium plays a very imdefect in the NO system [17, 39, 40] . portant role in the regulation of vascular tone through the Nevertheless, dihydropyridine CCBs seem to mediate release of different vasoactive substances. Results of recent part of their pharmacological effect by increasing endoinvestigations indicate that abnormal endothelial function, thelial NO production via a calcium-dependent mechanism manifested as impaired vascular relaxation response to [44] . In addition, the influence on endothelial NO proendothelium-dependent agonists, exists in some carduction may be responsible for some concomitant actions diovascular conditions [9, 10, [15] [16] [17] [18] [19] [20] [21] . It is well established of these vasodilators, such as their antiproliferative and that endothelium-dependent vasodilation is impaired in the antiatherosclerotic properties [45, 46] . experimental model of hypertension as well as in hypertenFinally, most recently, beneficial effects of ascorbic acid sive patients. Nevertheless, some animal studies suggest on endothelial dysfunction in forearm vessels in diabetic that endothelial impairment is secondary to hypertension, patients [47] , cigarette smoking [48] , ischemic heart while other studies indicate that in humans this alteration is disease [49] , and in epicardial coronary arteries of hyprimary to the hypertensive disease. This latter concept is pertensive patients [50] have been reported. In fact, there is based on previous studies in animal models of hypertenevidence from experimental studies that an excess of sion that have demonstrated the improvement of impaired superoxide anions in the arterial vascular bed could vascular relaxation after BP normalization [37, 38] .
account for the depressed ACh-induced vasodilation in Basal formation of NO and the effect of ACh infusion hypertension. Grunfeld and co-workers reported in geon the release of NO were found to be reduced in netically hypertensive rats that the major cause of the hypertensive patients, [10, 39, 40] whereas flow-induced decreased NO concentration is that although the rate of vasodilation was maintained [41] . However, this defect production is nearly normal, it is scavenged as it is seems not to be related to a decreased availability of the produced by excess superoxide anions [51] . The CCBs are natural substrate for NO production [39] nor is it a antioxidant compounds and their beneficial effects on consequence of a specific defect of the endothelial cell endothelial function, as reported in our study, might be surface receptor [42] , but it is probably related to a more related to this mechanism. generalized abnormality of endothelial vasodilator function [43] .
Conclusions 4.2. Antihypertensive treatment and vascular relaxation
The isradipine treatment is very effective in lowering for Previous reports demonstrated that chronic ACE-ina long-time, the BP in patients affected by mild to hibitors treatment failed to restore impaired endotheliummoderate hypertension. Moreover, the CCB isradipine dependent relaxation in hypertensive patients [23] [24] [25] . On seems to be able to improve the impaired ACh-induced the contrary, Hirooka et al. [26] reported that the ACEvasodilation in hypertensive patients. Nevertheless, further inhibitor captopril, but not CCB nifedipine, may acutely investigations are needed to identify the mechanism by improve the impaired endothelium-dependent forearm which isdradipine exerts this beneficial effect on vascular vasodilation in hypertensives. In our study, chronic isendothelium. radipine treatment improves endothelium-dependent vascular relaxation as is proven by the significant increase of FBF during ACh infusion (179.7% after two months, and 170.7% after six months). For the first time, our findings Acknowledgements demonstrate that antihypertensive treatment with a CCB may improve the endothelium-dependent vasodilation for a
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